newsfilter
← Latest News
GlobeNewswire·

Clarus Therapeutics Reports First Quarter 2022 Financial and Operating Results

First quarter 2022 net revenue increased 72% year-over-year to $4.0 million First quarter 2022 total prescription growth for JATENZO® increased 12% sequentially and increased 75% year-over-year Conference call and webcast today at 5:15 p.m. ET